Editas Medicine
AWARDS
NEWS
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
A look at three small biotech companies that appear to be leading the CRISPR race.
A look at a biotech company that represents a solid trend in the industry.
It’s not always easy to see when a company is a “disruptor,” which is to say, that it causes a paradigm shift in how an industry operates.
The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
JOBS
IN THE PRESS